As we previously showed that JAK inhibition prevented the anti-inflammatory effects of IFN-β on LPS-induced IL-8 expression in CF, our next step was to determine whether ruxolitinib affected neutrophil migration. This evidence concerns the gene CXCL8 and cystic fibrosis.